When was Full-Life Technologies founded?

Full-Life Technologies was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is Full-Life Technologies located?

Full-Life Technologies is headquartered in Shanghai, China.

How many employees does Full-Life Technologies have?

As of May 31, 2026, the latest employee count at Full-Life Technologies is 65.

Is Full-Life Technologies a funded company?

Full-Life Technologies is a funded company, having raised a total of $350M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 21, 2021.

When was the latest funding round of Full-Life Technologies?

Full-Life Technologies' latest funding was a $***** Series D round on May 18, 2026, with participation from 9 investors.

Where does Full-Life Technologies rank among its competitors?

Full-Life Technologies ranks 240th amongst 2494 active competitors, of which 869 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Full-Life Technologies, which secured $110M in May, 2026.

Who are the top competitors of Full-Life Technologies?

Full-Life Technologies' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Full-Life Technologies secured the most recent funding round in May, 2026.

Full-Life Technologies - 2026 Company Profile, Team, Funding & Competitors

Full-Life Technologies is a series D company based in Shanghai (China), founded in 2021 by HongHoi Ting, HH Ting and Nicholas Chung Lim Wong. It operates as a Provider of discovery, development, production, and logistics services for of nuclear medicines. Full-Life Technologies has raised $350M in funding from investors like Chengwei Capital, Junson Capital and Sequoia Capital China. The company has 2494 active competitors, including 869 funded and 615 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines.

Company Details

Provider of discovery, development, production, and logistics services for of nuclear medicines. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals. It manufactures radiopharmaceutical drug products.

Website: full-life.com
Email ID: *****@t-full.com

Key Metrics

Founded Year

2021

Location

Shanghai, China

Stage

Series D

Total Funding

$350M in 8 rounds

Latest Funding Round

Series D, May 18, 2026, $*****

Investors

Chengwei Capital & 19 more

Ranked

240^th among 2494 active competitors

Employee Count

65 as on May 31, 2026

Investment & Acquisitions

Focus-X Therapeutics

Similar Companies

Molecular Partners & 93 more

View Full-Life Technologies' full profile

Full-Life Technologies has raised a total funding of $350M over 8 rounds. Its first funding round was on Dec 21, 2021. Its latest funding round was a Series D round on May 18, 2026 for $*****. 9 investors participated in its latest round. Full-Life Technologies has 20 institutional investors.

Here is the list of recent funding rounds of Full-Life Technologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 18, 2026	6641768	Series D	1885961	9014339	7503700	5417500
May 18, 2026	1145925	Conventional Debt	7569002	4631298	8888626	7172098
Sep 30, 2025	6670654	Series C	9415222	5446095	Junson Capital	Lapam Capital & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Full-Life Technologies's funding rounds and investors

The founders of Full-Life Technologies are HongHoi Ting, HH Ting and Nicholas Chung Lim Wong.

Here are the details of Full-Life Technologies' key team members:

HongHoi Ting: Co-Founder of Full-Life Technologies.
HH Ting: Co-Founder And Chief Strategy Officer of Full-Life Technologies.
Nicholas Chung Lim Wong: Coo And Co-Founder of Full-Life Technologies.

View details of Full-Life Technologies's Founder profiles and Board Members

Full-Life Technologies' employee count trend

Full-Life Technologies has 65 employees as of May 26. Here is Full-Life Technologies's employee count trend over the years:

Employee count trend for Full-Life Technologies

Uncover Full-Life Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Full-Life Technologies include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of Full-Life Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	71/100
240th	Full-Life Technologies 2021, Shanghai (China), Series D	Provider of discovery, development, production, and logistics services for of nuclear medicines	$350M	Prosperity7 Ventures, Summer Capital & 18 others	57/100